Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
regenerating agents
- Development stage
- Unknown
- Lead developer
- OTR3
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical, Ophthalmic
01
Overview
ReGeneraTing Agents (RGTA) are a family of chemically engineered, biodegradable polymers designed to mimic the structural and functional properties of heparan sulfates within the extracellular matrix (ECM). Developed by OTR3, these agents act by binding to and protecting heparin-binding growth factors (HBGFs) and matrix proteins from proteolytic degradation, thereby restoring the microenvironment necessary for natural tissue repair. By stabilizing the ECM scaffold, RGTAs facilitate the healing of chronic wounds, corneal ulcers, and surgical scars. They are typically applied topically as solutions or incorporated into dressings.
- Brand names
- CacicolCacipliq20Cacipliq-20Cacipliq 20RGTA
- Other names
- ReGeneraTing AgentsRGTAheparan sulfate mimicsheparan sulfate mimetics
02
Targets
ELANE (Human Neutrophil Elastase)PLG (Plasminogen)VEGFA (Vascular endothelial growth factor A)Heparan sulfate binding sites on extracellular matrix structural proteinsFGF2CTSG (Cathepsin G)
Beyond the preview
Go deeper on regenerating agents.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on regenerating agents.